Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA

• Status: Not yet recruiting
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Use HeprAN ™ membrane (coated with heparin) should be allow the success of dialysis sessions, with adequate dialysis parameters, in patients treated by long-term anticoagulation with VKA, without addition of heparin perdialytic.

Less use of heparin (UFH or LMWH) during hemodialysis session should be allow a decrease of bleedings (moderate or major) and blood transfusions for hemodialysed patients with HeprAN ™ membrane and treated by long-term anticoagulation with VKA

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CHU de Reims
• Treatments: Heparin

Criteria

inclusion criteria :

• 18 years old and older

• chronic hemodialysis for at least 3 months

• treated by long-term anticoagulation with VKA

• hemodialysis with the HeprAN® membrane

• per dialytic heparin therapy (UFH or LMWH)

• dialyzed at Reims University Hospital

• agreeing to participate in the study

Exclusion criteria

• chronic hemodialysis without per dialytic heparin

• Patient dialized with single lumen catheter for vascular access

• less than 18 years old

• pregnant or lactating women

• protected by law